Skip to content
National Association of Attorneys General
  • For Members
    • How Do I…?
    • Member Benefits
    • Scholarships & Nominations
    • Specialized Services
    • Committees
    • Office Support
    • Member Directory
    • Account & Access
  • Events & Training
    • Event Calendar
    • Upcoming Programs
    • Training Opportunities
    • On-Demand Resources
    • CLE Credit
    • Mobile Training Requests
    • Our Faculty
  • Resources
    • Policy Letters
    • Reports & Publications
    • Research & Data
    • Attorney General Journal
    • Newsroom
    • Databases & Tools
    • Public Resources
  • Attorney Generals
    • What Attorneys General Do
    • Attorneys General Office 101
    • Find my AG
    • How AGs Are Selected
    • Issues Attorney Generals Work On
    • Consumer Complaint Guidance
    • Attorney General Elections
    • Past Attorneys General
    • Careers in Attorney General Offices
  • NAMFCU
    • History of NAMFCU
    • About NAMFCU
    • NAMFCU
    • About the Medicaid Fraud Control Units
    • NAMFCU Trainings
    • MFCU Member Hub
    • Reporting Fraud and Abuse
    • Careers with a MFCU
  • About
    • About Us
    • NAAG History
    • Leadership
    • Staff
    • Regions
    • Careers at NAAG
    • FAQs
    • SAGE
    • Contact Us
  • Log In
PUBLIC RESOURCES           NEWSROOM           CONTACT US
FIND MY AG         CREATE ACCOUNT
National Association of Attorneys General
  • For Members
    • How Do I…?
    • Member Benefits
    • Scholarships & Nominations
    • Specialized Services
    • Committees
    • Office Support
    • Member Directory
    • Account & Access
  • Events & Training
    • Event Calendar
    • Upcoming Programs
    • Training Opportunities
    • On-Demand Resources
    • CLE Credit
    • Mobile Training Requests
    • Our Faculty
  • Resources
    • Policy Letters
    • Reports & Publications
    • Research & Data
    • Attorney General Journal
    • Newsroom
    • Databases & Tools
    • Public Resources
  • Attorney Generals
    • What Attorneys General Do
    • Attorneys General Office 101
    • Find my AG
    • How AGs Are Selected
    • Issues Attorney Generals Work On
    • Consumer Complaint Guidance
    • Attorney General Elections
    • Past Attorneys General
    • Careers in Attorney General Offices
  • NAMFCU
    • History of NAMFCU
    • About NAMFCU
    • NAMFCU
    • About the Medicaid Fraud Control Units
    • NAMFCU Trainings
    • MFCU Member Hub
    • Reporting Fraud and Abuse
    • Careers with a MFCU
  • About
    • About Us
    • NAAG History
    • Leadership
    • Staff
    • Regions
    • Careers at NAAG
    • FAQs
    • SAGE
    • Contact Us
  • Log In

State and Territory Attorneys General Urge FDA to Take Action Against Counterfeit and Illegally Sold GLP-1 Drugs

Home / NAAG, Attorneys General / State and Territory Attorneys General Urge FDA to Take Action Against Counterfeit and Illegally Sold GLP-1 Drugs
February 19, 2025 NAAG, Attorneys General
Share this

For Release: February 19, 2025

Washington, D.C.  – The National Association of Attorneys General (NAAG) sent a letter on behalf of a bipartisan coalition of 38 state and territory attorneys general requesting that the Food and Drug Administration take swift action against bad actors who are endangering consumers with counterfeit forms of the weight loss and diabetes drugs Mounjaro, Zepbound, Ozempic, and Wegovy (GLP-1 drugs).

The letter states that “online retailers are illegally selling the active ingredients of GLP-1 drugs directly to consumers, without a prescription. These retailers claim that the active ingredients they sell are ’for research purposes only’ or ’not for human consumption.’ 1 In reality, these companies advertise directly to consumers on social media, claiming that their products are an easier and more affordable way to obtain GLP-1 drugs. 2 Much like with counterfeit versions, these active ingredients come from unregulated, undisclosed sources and pose risks of contamination and inclusion of foreign substances.” 3

The letter declares that the Food and Drug Administration has the expertise and resources to stop the bad conduct and deceptive practices by counterfeit drug manufacturers and that they should increase enforcement actions against compounding pharmacies illegally participating in this market. It also encourages the FDA to partner with state pharmacy boards to ensure compounded GLP-1 drugs are produced safely and in sanitary environments.

The following jurisdictions, co-led by South Carolina, Colorado, Illinois, and Tennessee joined today’s letter:

Alaska, Arkansas, California, Connecticut, Delaware, District of Columbia, Georgia, Hawaii, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Nevada, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Utah, Vermont, Virgin Islands, Virginia, West Virginia, and Wisconsin.

###

The National Association of Attorneys General (NAAG) is the nonpartisan national forum for America’s attorneys general and their staff. NAAG provides a community for members to collaboratively address issues important to their work and resources to support attorneys general in protecting the rule of law and the United States Constitution.


Endnotes

  1. See Jordyn Belcourt et al., Bypassing Prescribers and Pharmacists: Online Purchasing of Semaglutide and Tirzepatide “For Research Purposes,” Annals of Pharmacotherapy, p.1 (2024). [↩]
  2. See https://www.wsj.com/health/healthcare/ozempic-mounjaro-no-prescription-websites-726b3928 [↩]
  3. https://www.nbcnews.com/health/health-news/ozempic-underworld-black-market-obesity-drugs-rcna174680 [↩]

Media Contact

media@naag.org

Sign-up to receive NAAG’s monthly newsletter.

Latest News

  • Bipartisan Coalition of 45 Attorneys General Backs Pharmacy Benefit Manager (PBM) Transparency Rule April 17, 2026
  • Supreme Court Report, Volume 33, Issue 10 April 8, 2026
  • Supreme Court Report, Volume 33, Issue 9 April 1, 2026
  • Bipartisan Coalition of Attorneys General Urges Congress to Pass Legislation Against Illicit Xylazine March 31, 2026
  • Supreme Court Report, Volume 33, Issue 8 March 23, 2026

Recent Posts

  • Bipartisan Coalition of 45 Attorneys General Backs Pharmacy Benefit Manager (PBM) Transparency Rule
  • Supreme Court Report, Volume 33, Issue 10
  • Supreme Court Report, Volume 33, Issue 9
  • Bipartisan Coalition of Attorneys General Urges Congress to Pass Legislation Against Illicit Xylazine
  • Supreme Court Report, Volume 33, Issue 8

Stay Connected

Get NAAG updates and training alerts.

Create an account and then select your preferred mailings (otherwise, we will send you everything).

Create Account
Set Marketing Preferences
Log In to Your Account
White Logo for the National Association of Attorneys General

1850 M Street NW, Suite 1200
Washington, DC  20036
Telephone: (202) 326-6000
support@naag.org

Our Work

  • Bankruptcy
  • Consumer Protection
  • Tobacco and Public Health
  • Center for Supreme Court Advocacy

Resources

  • Attorney General Journal
  • CLE Policy and Guidelines
  • Event Calendar
  • NAAG Policy Letters
  • Reports & Publications

ABOUT

  • Leadership
  • Staff
  • NAAG History
  • Mission Foundation
  • Careers at NAAG
  • Contact Us

© 2026 Copyright National Association of Attorneys General

Website by Yoko Co

Internal Feedback / Report an Error

Request an Update / Report an Error

The change you are requesting will be linked to this page. The URL for the page will be included in a hidden field when the form is submitted.
Please enter your change or describe your request. Be sure to reference where the error appears on the page and what needs to be done specifically.
Upload any files that need to be linked to this page. PDF only. Submit another request if you have more than five files to upload.
Drop files here or
Accepted file types: pdf, docx, xls, Max. file size: 128 MB, Max. files: 5.

    Who is requesting this change?(Required)

    Scroll To Top

    Insert/edit link

    Enter the destination URL

    Or link to existing content

      No search term specified. Showing recent items. Search or use up and down arrow keys to select an item.
        This site is registered on Toolset.com as a development site.
        To provide you more clarity about how we collect, store and use personal information, and your rights to control that information, we have updated our privacy policy, which also explains how we use cookies. You consent to our cookies if you continue to use our website.